CHECKMATE PHARMACEUTICALS IN (CMPI)

US1628181083 - Common Stock

10.5  +0.02 (+0.19%)

Fundamental Rating

2

Taking everything into account, CMPI scores 2 out of 10 in our fundamental rating. CMPI was compared to 588 industry peers in the Biotechnology industry. While CMPI has a great health rating, there are worries on its profitability. CMPI does not seem to be growing, but still is valued expensively.



0

1. Profitability

1.1 Basic Checks

CMPI had negative earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -94.34%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CMPI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

7

2. Health

2.1 Basic Checks

The number of shares outstanding for CMPI remains at a similar level compared to 1 year ago.
There is no outstanding debt for CMPI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 4.87 indicates that CMPI is not in any danger for bankruptcy at the moment.
CMPI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.87
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

CMPI has a Current Ratio of 5.20. This indicates that CMPI is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 5.20 indicates that CMPI has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 5.2
Quick Ratio 5.2

1

3. Growth

3.1 Past

CMPI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 69.23%, which is quite impressive.
EPS 1Y (TTM)69.23%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-12.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

CMPI is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.24% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-8.64%
EPS Next 2Y8.68%
EPS Next 3Y-15.32%
EPS Next 5Y5.24%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

CMPI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CMPI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -2.6

4.3 Compensation for Growth

CMPI's earnings are expected to decrease with -15.32% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.68%
EPS Next 3Y-15.32%

0

5. Dividend

5.1 Amount

CMPI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CHECKMATE PHARMACEUTICALS IN

NASDAQ:CMPI (5/27/2022, 7:00:01 PM)

10.5

+0.02 (+0.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap231.40M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -94.34%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 5.2
Quick Ratio 5.2
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)69.23%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-8.64%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y